An analysis of more than 157,000 matched patients aged 60 and older without diabetes linked GLP-1 weight-loss drugs to an 18% lower risk of age-related macular degeneration versus other obesity medicines.
The study compared nearly 79,000 GLP-1 users with a similar number of non-GLP-1 users and found the apparent benefit rose to 30% for unspecified AMD, while no clear association appeared for wet AMD.
Researchers said the effect could reflect direct retinal neuroprotection—possibly through reduced retinal inflammation—or simply greater weight loss, which itself may lower systemic inflammation and AMD risk.
The findings remain observational and short-term: median follow-up was 1 year for GLP-1 users and 2.5 years for the comparison group, leaving durability and causation unproven.
The Taiwan-led team focused on obese patients without diabetes to strip out blood-sugar effects seen in earlier GLP-1 studies and called for prospective mechanistic research with ophthalmologic follow-up.